Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections.

Autor:	Olivares E; University of Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, EA7290, Institut de Bactériologie, Strasbourg, France.; BioFilm Pharma SAS, Saint-Beauzire, France., Badel-Berchoux S; BioFilm Control SAS, Saint-Beauzire, France., Provot C; BioFilm Pharma SAS, Saint-Beauzire, France.; BioFilm Control SAS, Saint-Beauzire, France., Prévost G; University of Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, EA7290, Institut de Bactériologie, Strasbourg, France., Bernardi T; BioFilm Pharma SAS, Saint-Beauzire, France.; BioFilm Control SAS, Saint-Beauzire, France., Jehl F; University of Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, EA7290, Institut de Bactériologie, Strasbourg, France.
Jazyk:	angličtina
Zdroj:	Frontiers in microbiology [Front Microbiol] 2020 Jan 09; Vol. 10, pp. 2894. Date of Electronic Publication: 2020 Jan 09 (Print Publication: 2019).
DOI:	10.3389/fmicb.2019.02894
Abstrakt:	Bacterial biofilms are highly recalcitrant to antibiotic therapies due to multiple tolerance mechanisms. The involvement of Pseudomonas aeruginosa in a wide range of biofilm-related infections often leads to treatment failures. Indeed, few current antimicrobial molecules are still effective on tolerant sessile cells. In contrast, studies increasingly showed that conventional antibiotics can, at low concentrations, induce a phenotype change in bacteria and consequently, the biofilm formation. Understanding the clinical effects of antimicrobials on biofilm establishment is essential to avoid the use of inappropriate treatments in the case of biofilm infections. This article reviews the current knowledge about bacterial growth within a biofilm and the preventive or inducer impact of standard antimicrobials on its formation by P. aeruginosa . The effect of antibiotics used to treat biofilms of other bacterial species, as Staphylococcus aureus or Escherichia coli , was also briefly mentioned. Finally, it describes two in vitro devices which could potentially be used as antibiotic susceptibility testing for adherent bacteria. (Copyright © 2020 Olivares, Badel-Berchoux, Provot, Prévost, Bernardi and Jehl.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu